FELIQS Corporation, a biotechnology company focused on rare pediatric retinal diseases, announced the completion of a $9 million Series A financing round. The funding was co-led by a major American pharmaceutical company and Beyond Next Ventures Inc., with additional contributions from the Japan Science and Technology Agency and existing investors. This investment marks a significant milestone for the company's lead candidate, FLQ-101, which is designed to prevent retinopathy of prematurity (ROP), a leading cause of blindness in premature infants.
FLQ-101 has received both Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration, highlighting its potential to address a substantial unmet medical need. The proceeds from this financing will support the acceleration of the Phase 1b/2 tROPhy-1 study of FLQ-101 in the United States, which is scheduled to begin in the summer of 2025. FLQ-101 is a once-daily oral or intravenous solution that promotes healthy retinal vascularization while protecting against inflammation and abnormal blood vessel growth.
Dr. Ken-ichiro (Nobu) Kuninobu, Co-Founder and CEO of FELIQS, expressed gratitude for the investor support, emphasizing the importance of advancing treatments for underserved pediatric populations. The investment enables FELIQS to expand its operational and clinical development teams and strengthen collaborative research initiatives in the U.S., paving the way for innovative solutions in pediatric ophthalmology.
The importance of this funding extends beyond the company's immediate goals. Retinopathy of prematurity remains a significant challenge in neonatal care, and effective treatments are limited. With FLQ-101's regulatory designations, FELIQS is positioned to expedite development and potentially bring a much-needed therapy to market. The involvement of a major pharmaceutical company and international investors underscores the global interest in addressing rare pediatric diseases.
By advancing the tROPhy-1 study, FELIQS aims to generate critical data on safety and efficacy, which could lead to broader clinical applications. The company's approach targets the underlying mechanisms of ROP, offering a novel therapeutic strategy compared to existing interventions. This development is closely watched by the pediatric ophthalmology community, as it represents a potential shift in how ROP is prevented and treated.
For more information, visit the company's website at FELIQS Corporation.
